Institute of Hematology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer Sci. 2010 May;101(5):1117-24. doi: 10.1111/j.1349-7006.2010.01515.x. Epub 2010 Jan 28.
Bone marrow (BM) neovascularization and vascular endothelial growth factor (VEGF) expression in multiple myeloma (MM) correlate with disease progression. Brain derived neurotrophic factor (BDNF) is highly expressed by malignant plasma cells isolated from the majority of MM patients. Recently, BDNF was identified as a potential proangiogenic factor for the promotion of endothelial cell survival, induction of neoangiogenesis in ischemic tissues, and increase of VEGF expression in neuroblastoma. Since tropomyosin receptor kinase B (TrkB), the receptor of BDNF, is expressed by stromal cells within the BM milieu, here we sought to evaluate the involvement of BDNF/TrkB in myeloma-marrow stroma interaction and its effects on BM angiogenesis. TrkB was abundantly expressed by bone marrow stromal cells (BMSCs) isolated from healthy donors. Stimulation of BMSCs with BDNF induced a time- and dose- dependent increase in VEGF secretion, which was completely abolished by K252alpha, an inhibitor of TrkB. BDNF triggered activation of signal transducer and activator of transcription 3 (STAT3) and activator protein-1 (AP-1), whereas STAT3 was involved in mediating VEGF expression. We further delineated the biological significance of BDNF in MM by using lentiviral short-interfering RNA (shRNA). When myeloma cells were cocultured with BMSCs in a noncontact Transwell system, VEGF levels in supernatants were significantly decreased when BDNF expression was knocked down. Furthermore, silencing of BDNF expression significantly inhibited xenograft tumor growth and angiogenesis, and prolonged survival in mouse model. Our studies demonstrate that BDNF, as a potential stimulator of angiogenesis, contributes to MM tumorgenesis; it mediates stromal-MM cell interactions via selective activation of specific receptor TrkB and downstream signal transducer STAT3, regulating VEGF secretion.
骨髓(BM)新生血管形成和血管内皮生长因子(VEGF)在多发性骨髓瘤(MM)中的表达与疾病进展相关。脑源性神经营养因子(BDNF)在大多数 MM 患者分离的恶性浆细胞中高度表达。最近,BDNF 被鉴定为一种潜在的促血管生成因子,可促进内皮细胞存活、诱导缺血组织中的新生血管形成,并增加神经母细胞瘤中 VEGF 的表达。由于 BDNF 的受体 tropomyosin receptor kinase B(TrkB)在 BM 微环境中的基质细胞中表达,因此我们在此评估了 BDNF/TrkB 在骨髓瘤-骨髓基质细胞相互作用及其对 BM 血管生成的影响。TrkB 在从健康供体分离的骨髓基质细胞(BMSC)中大量表达。BDNF 刺激 BMSC 会引起 VEGF 分泌的时间和剂量依赖性增加,而 TrkB 的抑制剂 K252alpha 则完全消除了这种增加。BDNF 触发信号转导和转录激活因子 3(STAT3)和激活蛋白-1(AP-1)的激活,而 STAT3 参与介导 VEGF 的表达。我们进一步利用慢病毒短发夹 RNA(shRNA)阐明了 BDNF 在 MM 中的生物学意义。当骨髓瘤细胞在非接触 Transwell 系统中与 BMSC 共培养时,当 BDNF 表达被敲低时,上清液中的 VEGF 水平显着降低。此外,BDNF 表达的沉默显着抑制异种移植肿瘤生长和血管生成,并延长了小鼠模型的存活时间。我们的研究表明,BDNF 作为一种潜在的血管生成刺激因子,有助于 MM 的肿瘤发生;它通过选择性激活特定受体 TrkB 和下游信号转导子 STAT3 来介导基质-MM 细胞相互作用,调节 VEGF 的分泌。